{"id":12598,"date":"2026-04-08T11:06:55","date_gmt":"2026-04-08T02:06:55","guid":{"rendered":"https:\/\/miragen.clinic\/blog\/can-rutinib-ointment-replace-opzelura-same-ingredients-different-realities\/"},"modified":"2026-07-02T00:43:00","modified_gmt":"2026-07-01T15:43:00","slug":"can-rutinib-ointment-replace-opzelura-same-ingredients-different-realities","status":"publish","type":"post","link":"https:\/\/miragen.clinic\/en\/blog\/can-rutinib-ointment-replace-opzelura-same-ingredients-different-realities\/","title":{"rendered":"Can Rutinib Ointment Replace Opzelura? | Same Ingredients, Different Realities"},"content":{"rendered":"\n<div class=\"wp-block-group alignwide has-global-padding is-layout-constrained wp-container-core-group-is-layout-134ed493 wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-group alignwide has-global-padding is-layout-constrained wp-container-core-group-is-layout-0958e68c wp-block-group-is-layout-constrained\">\n<p class=\"wp-block-paragraph\">Among patients visiting for chronic dermatitis, there are rare cases where individuals purchase Rutinib ointment through overseas direct buying services. They often ask, &#8220;I tried it because it&#8217;s said to have the same ingredients as the new drug Opzelura; is it okay to use?&#8221; This is a difficult question to answer briefly. <\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/04\/opzelura-rutinib-vertical-comparison.webp\" alt=\"A product shot featuring Opzelura 1.5% cream and Rutinib cream (generic) tubes, both containing the same ingredient ruxolitinib, placed side-by-side vertically to compare topical JAK inhibitor formulations at a glance.\" class=\"wp-image-10857\" title=\"Comparison of Opzelura and Rutinib Ointment Tubes\"\/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">It is true that both claim to contain 1.5% ruxolitinib. However, having the same ingredients is not the same as having the same level of evidence. I have summarized the details in this post that I could not fully explain in the consultation room.  <\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table><thead><tr><th>Item<\/th><th>Opzelura<\/th><th>Rutinib Ointment<\/th><\/tr><\/thead><tbody><tr><td>Main Ingredient<\/td><td>Ruxolitinib 1.5%<\/td><td>Ruxolitinib 1.5%<\/td><\/tr><tr><td>Developer<\/td><td>Incyte (Original Developer)<\/td><td>Drug International, etc. (Non-original Developer)<\/td><\/tr><tr><td>Approval<\/td><td>FDA Approved (Atopic Dermatitis 2y+, Vitiligo 12y+)<\/td><td>No FDA Approval<\/td><\/tr><tr><td>Phase 3 Clinical Trials<\/td><td>Multiple publications including TRuE-AD, TRuE-V<\/td><td>No independent Phase 3 publications<\/td><\/tr><tr><td>Formulation Validation<\/td><td>Passed FDA Review<\/td><td>No public data available<\/td><\/tr><tr><td>Korean Approval<\/td><td>Unapproved<\/td><td>Unapproved<\/td><\/tr><tr><td>Purchase Route<\/td><td>Requires overseas prescription<\/td><td>Available for online purchase (some cases)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Both Opzelura and Rutinib are cream formulations. However, since many people search for &#8216;Rutinib ointment&#8217; rather than &#8216;Rutinib cream,&#8217; that term is used in this post. <\/p>\n<\/blockquote>\n\n\n\n<div class=\"wp-block-rank-math-toc-block has-custom-color-5-color has-custom-color-2-background-color has-text-color has-background has-link-color wp-elements-f3238be6d414bda504ddce6771250f54\" style=\"padding-top:var(--wp--preset--spacing--superbspacing-xsmall);padding-right:0;padding-bottom:var(--wp--preset--spacing--superbspacing-xsmall);padding-left:0\" id=\"rank-math-toc\"><h2>\ubaa9\ucc28<\/h2><nav><ul><li><a href=\"#sec-1\">What Kind of Ingredient is Ruxolitinib?<\/a><\/li><li><a href=\"#sec-2\">Clinical Evidence for Opzelura<\/a><\/li><li><a href=\"#sec-3\">Why Rutinib Ointment and Opzelura are Different<\/a><\/li><li><a href=\"#sec-4\">Options Available in Korea<\/a><\/li><li><a href=\"#sec-faq\">Frequently Asked Questions<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-1\">What Kind of Ingredient is Ruxolitinib?<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">Ruxolitinib is an ingredient that simultaneously inhibits JAK1 and JAK2. JAK is an enzyme that transmits inflammatory signals within immune cells; in atopic dermatitis, cytokines such as IL-4, IL-13, and IL-31 operate excessively through this pathway. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In particular, IL-31 is a key mediator of itching. The cycle of itching \u2192 scratching \u2192 skin barrier damage \u2192 worsening inflammation is the primary axis that makes atopic dermatitis chronic, and JAK inhibitors block the itching signal, which is the starting point of this cycle. Therefore, they have a different point of action than steroids. While steroids suppress a wide range of inflammation all at once, JAK inhibitors are closer to drugs that selectively cut off specific signaling pathways.   <\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/06\/jak-pathway-ruxolitinib-mechanism-v2-EN.png\" alt=\"A medical illustration showing the mechanism of action where ruxolitinib, the main ingredient in Rutinib ointment and Opzelura, inhibits JAK1 and JAK2 to block atopic itching and inflammatory signals.\" class=\"wp-image-10085\" title=\"Ruxolitinib JAK Pathway Inhibition Mechanism\"\/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The same pathway operates in vitiligo. Because the JAK-STAT pathway is involved in the immune response that attacks melanocytes, blocking this pathway allows for the possibility of melanocytes recovering their function. However, since destroyed cells must grow back, it takes much longer.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-2\">Clinical Evidence for Opzelura<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Atopic Dermatitis: Rapid Itch Reduction is a Strength<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In Phase 3 studies testing 1,249 patients with mild-to-moderate atopic dermatitis for 8 weeks, the treatment success rate (IGA-TS) was approximately 50%, significantly higher than the approximately 15% of the control cream.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33957195\/\" target=\"_blank\" rel=\"noopener\">1<\/a><\/sup> Itching began to decrease within 12 hours after application, a speed comparable to that of steroids.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Subsequent pooled analyses of multiple clinical trials in patients with moderate atopic dermatitis showed significant efficacy even when compared to oral JAK inhibitors and biologics.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906354\/\" target=\"_blank\" rel=\"noopener\">2<\/a><\/sup> Furthermore, in a direct comparison with 0.1% triamcinolone (a Class 5 steroid), the EASI75 achievement rate at 4 weeks was 56% versus 47%, showing results similar to or slightly better than moderate-strength steroids.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037525\/\" target=\"_blank\" rel=\"noopener\">3<\/a><\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Safety and efficacy were also confirmed in children (2\u201311 years) and adolescents,<sup><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40378883\/\" target=\"_blank\" style=\"color: inherit;\" rel=\"noopener\">4<\/a><\/sup> and a recent analysis synthesizing five clinical trials reaffirmed significant improvements in both IGA-TS and EASI75.<sup><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41556257\/\" target=\"_blank\" style=\"color: inherit;\" rel=\"noopener\">5<\/a><\/sup><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Vitiligo: Must Be Viewed Much More Slowly<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The progression of vitiligo is entirely different. In the TRuE-V1\/V2 studies, the facial F-VASI75 achievement rate at 24 weeks was approximately 30%, and it took up to 52 weeks for meaningful repigmentation to appear in about half of the patients.<sup><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36260792\/\" target=\"_blank\" style=\"color: inherit;\" rel=\"noopener\">6<\/a><\/sup> Opzelura received FDA approval for the treatment of vitiligo in July 2022, making it the first FDA-approved treatment for vitiligo. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a 104-week long-term safety analysis, there were no prominent signals of the most concerning cardiovascular events, blood clots, or serious infections.<sup><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41125994\/\" target=\"_blank\" style=\"color: inherit;\" rel=\"noopener\">7<\/a><\/sup> The most common adverse reactions were nasopharyngitis (7.2%) and application site acne (6.0%).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-3\">Why Rutinib Ointment and Opzelura are Different<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">The core issue is <strong>what verification procedures each product has undergone<\/strong>. All clinical data cited above originated from the Opzelura program. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rutinib ointment, which can be purchased online through direct buying, is a product of Drug International in Bangladesh. It is not an FDA-approved generic, but a product manufactured in a market with a different regulatory environment. Even with the same 1.5% ruxolitinib, the cream base, preservatives, skin absorption profile, manufacturing process, and distribution temperature stability vary by product, and bioequivalence data is not publicly available. This is why one cannot conclude that &#8220;same ingredients mean same effects.&#8221;   <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The price difference also arises at this point. The original developer&#8217;s drug bears the burden of clinical development, approval, and post-market surveillance, while non-original developer products enter the market without that process. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The most practical problem is that <strong>neither Opzelura nor Rutinib ointment is officially approved in Korea<\/strong><strong>.<\/strong> In the event of an adverse reaction, it is difficult for Korean doctors to take appropriate measures because they lack experience with these ointments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-4\">Options Available in Korea<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Topical Treatment: There are Proven Options<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">When non-steroidal anti-inflammatory ointments are needed for atopic dermatitis treatment, I consider <a href=\"https:\/\/miragen.clinic\/en\/protopic\/\" data-type=\"page\" data-id=\"6419\">Protopic<\/a> and <a href=\"https:\/\/miragen.clinic\/en\/elidel\/\" data-type=\"page\" data-id=\"6418\">Elidel<\/a> before Rutinib ointment. Both can be officially prescribed in Korea and have clinical data accumulated over decades. <\/p>\n\n\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"572\" data-id=\"7769\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/03\/protopic-ointment-product-photo.jpg\" alt=\"A real photo of a 10g tube of Protopic (tacrolimus) 0.1% ointment, a non-steroidal calcineurin inhibitor, prescribed as a steroid alternative. \" class=\"wp-image-7769\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"572\" data-id=\"3733\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/01\/elidel-cream-product-photo.jpg\" alt=\"A real-life photo of Elidel (pimecrolimus) 1% cream, a non-steroidal calcineurin inhibitor, in a 10 g tube&#x2014; a prescription medication used as a steroid alternative; as a cream, it feels lighter to apply than an ointment\" class=\"wp-image-3733\"\/><\/figure>\n<\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">For reference, there is one topical JAK inhibitor that can be officially prescribed in Korea. It is Anzupgo Cream (delgocitinib), approved in September 2025, but its indication is limited to chronic hand eczema and cannot be used for atopic dermatitis. Details regarding <a href=\"https:\/\/miragen.clinic\/en\/blog\/anzupgo-cream-pharmacy-cost-690000-krw-can-it-be-used-for-atopic-dermatitis\/\" data-type=\"post\" data-id=\"10146\">Anzupgo Cream<\/a> are covered in a separate post. <\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/04\/anzupgo-delgocitinib-cream-tube.jpg\" alt=\"A tube of Anzupgo Cream (delgocitinib), the only topical JAK inhibitor approved in Korea, which, unlike Rutinib ointment or Opzelura, can only be used for the indication of chronic hand eczema.\" class=\"wp-image-10149\" title=\"Anzupgo Cream (Delgocitinib) Product\"\/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Oral JAK Inhibitors: There are Approved Drugs in Korea<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In Korea, most JAK inhibitors are officially approved for moderate-to-severe atopic dermatitis in oral form rather than topical form.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table><thead><tr><th>Drug<\/th><th>Ingredient<\/th><th>Selectivity<\/th><th>Korean Approval<\/th><\/tr><\/thead><tbody><tr><td>Olumiant<\/td><td>Baricitinib<\/td><td>JAK1\/2<\/td><td>Moderate-to-severe atopic dermatitis (Adults)<\/td><\/tr><tr><td>Rinvoq<\/td><td>Upadacitinib<\/td><td>JAK1<\/td><td>Moderate-to-severe atopic dermatitis (12y+)<\/td><\/tr><tr><td>Cibinqo<\/td><td>Abrocitinib<\/td><td>JAK1<\/td><td>Moderate-to-severe atopic dermatitis (12y+)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/04\/rinvoq-upadacitinib-white-bg.png\" alt=\"A bottle and pills of Rinvoq (upadacitinib) 15mg, an oral JAK inhibitor approved in Korea that can be considered instead of overseas direct purchase of Opzelura or Rutinib ointment, placed on a white background.\" class=\"wp-image-10092\" title=\"Rinvoq (Upadacitinib) Product\"\/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">These drugs block the same JAK pathway but act systemically because they are oral medications. Therefore, they show efficacy in a wide range of moderate-to-severe atopic dermatitis, and pooled analyses of clinical trials in children also report significant efficacy and manageable safety profiles.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39909768\/\" target=\"_blank\" rel=\"noopener\">8<\/a><\/sup> <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, these are not drugs that can be prescribed immediately. To receive health insurance coverage (Calculation Exception), one must have an <strong>EASI score of 23 or higher after using topical treatments for at least 4 weeks and systemic immunosuppressants (such as Cypol-N) for at least 3 months<\/strong>. If health insurance is applied, the out-of-pocket cost is reduced to about 10% (approximately 60,000 KRW per month for Rinvoq), but if not applied, Rinvoq costs approximately 600,000 KRW per month.  <\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/06\/atopic-dermatitis-treatment-steps-korea-v2-EN.png\" alt=\"An illustration showing the flow of atopic dermatitis treatment stages in Korea to be reviewed before direct purchase of Opzelura or Rutinib ointment, ranging from topical treatments to systemic immunosuppressants and oral JAK inhibitors.\" class=\"wp-image-10086\" title=\"Step-by-step Treatment Options for Atopic Dermatitis in Korea\"\/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This process, including cyclosporine prescription and EASI evaluation, is usually conducted at tertiary hospitals. In local clinics, topical treatments such as <a href=\"https:\/\/miragen.clinic\/en\/topical-steroids\/\" data-type=\"page\" data-id=\"6430\">steroids<\/a>, <a href=\"https:\/\/miragen.clinic\/en\/protopic\/\" data-type=\"page\" data-id=\"6419\">Protopic<\/a>, and <a href=\"https:\/\/miragen.clinic\/en\/elidel\/\" data-type=\"page\" data-id=\"6418\">Elidel<\/a> are the primary tools, and if control is not achieved, patients are referred to tertiary hospitals. It is much safer to follow these steps than to purchase unapproved products from overseas.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Let&#8217;s return to the question. If you ask, &#8220;Is Rutinib ointment the same ingredient as Opzelura?&#8221; the answer is yes, it is 1.5% ruxolitinib (at least it claims to be). However, it does not possess the same evidence, quality control, or tracking system. Furthermore, neither ointment is approved in Korea, and there are official treatment steps that can be safely attempted before considering overseas direct purchase.   <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-dots\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">References<\/h3>\n\n\n\n<ol class=\"wp-block-list has-custom-color-5-color has-text-color has-link-color has-superbfont-xxsmall-font-size wp-elements-b9e3f1a90766a9085522cb2a2719cef3\">\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33957195\/\" target=\"_blank\" rel=\"noopener\"><em>Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863-872.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906354\/\" target=\"_blank\" rel=\"noopener\"><em>Gooderham MJ, Hong HC, Wang D, et al. Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis. Dermatol Ther (Heidelb). 2025;15(11):3313-3328.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037525\/\" target=\"_blank\" rel=\"noopener\"><em>Kircik L, Sturm D, Kallender H, et al. Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis. J Drugs Dermatol. 2025;24(10):1036-1039.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40378883\/\" target=\"_blank\" rel=\"noopener\"><em>Eichenfield LF, Stein Gold LF, Simpson EL, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3. J Am Acad Dermatol. 2025;93(3):689-698.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41556257\/\" target=\"_blank\" rel=\"noopener\"><em>Ghanem L, Mendoza-Mill\u00e1n DL, Lopes BB, et al. Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review and meta-analysis. Pediatr Allergy Immunol. 2026;37(1):e70281.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36260792\/\" target=\"_blank\" rel=\"noopener\"><em>Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022;387(16):1445-1455.  <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41125994\/\" target=\"_blank\" rel=\"noopener\"><em>Rosmarin D, Pandya AG, Passeron T, et al. Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. Dermatol Ther (Heidelb). 2025;15(12):3703-3716.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39909768\/\" target=\"_blank\" rel=\"noopener\"><em>Kawamoto N, Murai H, Nogami K, et al. Efficacy and safety of systemic targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis. Allergol Int. 2025;74(3):424-434.   <\/em><\/a><\/li>\n<\/ol>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignwide is-style-superbaddons-card has-custom-color-2-background-color has-background has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-top-left-radius:16px;border-top-right-radius:16px;border-bottom-left-radius:16px;border-bottom-right-radius:16px\">\n<h2 class=\"wp-block-heading has-custom-color-4-color has-text-color has-link-color wp-elements-fec4206f5af5888537ae11aefd49af22\" id=\"sec-faq\">Frequently Asked Questions<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-custom-color-5-color has-alpha-channel-opacity has-custom-color-5-background-color has-background is-style-wide\" style=\"margin-top:var(--wp--preset--spacing--superbspacing-xsmall);margin-bottom:var(--wp--preset--spacing--superbspacing-xsmall)\"\/>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list \">\n<div id=\"faq-1\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Are Rutinib ointment and Opzelura the same drug?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Both contain 1.5% ruxolitinib as the main ingredient. However, Opzelura is a product of the original developer (Incyte), is FDA-approved, and has extensive Phase 3 clinical trial data. Rutinib ointment is a non-original developer product from overseas, and no independent Phase 3 publications have been confirmed. While the ingredients are the same, the formulation, quality control, and level of evidence differ.   <\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-2\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Can Rutinib ointment be prescribed in Korea?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>No. Neither Opzelura nor Rutinib ointment is approved in Korea. Even if purchased through overseas direct buying, it is used without a prescription, and since doctors in Korea with experience with this drug are very rare, it is difficult to take appropriate action in case of adverse reactions. If you need treatment for atopic dermatitis, we recommend starting with topical treatments approved in Korea (Protopic, Elidel), and if control is difficult with topical treatment, consult with a tertiary hospital regarding systemic treatment pathways.   <\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-3\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Can anyone use oral JAK inhibitors?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>No. To receive health insurance benefits, one must have an EASI score of 23 or higher even after trying topical treatments and systemic immunosuppressants (such as cyclosporine) in sequence. Blood tests and infection screening are required before prescription, and regular monitoring is necessary during medication, so the process is primarily conducted at tertiary hospitals.  <\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group has-custom-color-2-background-color has-background has-global-padding is-layout-constrained wp-container-core-group-is-layout-ffa602f6 wp-block-group-is-layout-constrained\" style=\"border-top-left-radius:16px;border-top-right-radius:16px;border-bottom-left-radius:16px;border-bottom-right-radius:16px;padding-top:0;padding-right:0;padding-bottom:0;padding-left:0\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8c970b27 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:40%\">\n<figure class=\"wp-block-image size-full\" style=\"margin-right:0;margin-left:0\"><img decoding=\"async\" width=\"600\" height=\"600\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/01\/doctor-han-namecard-profile.png\" alt=\"\" class=\"wp-image-3537\"\/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:var(--wp--preset--spacing--superbspacing-small);padding-right:var(--wp--preset--spacing--superbspacing-small);padding-bottom:var(--wp--preset--spacing--superbspacing-small);padding-left:var(--wp--preset--spacing--superbspacing-small);flex-basis:60%\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-dec8e639 wp-block-group-is-layout-constrained\" style=\"padding-top:0;padding-right:0;padding-bottom:0;padding-left:0\">\n<p class=\"has-custom-color-3-color has-text-color has-link-color has-superbfont-large-font-size wp-elements-9a43ded5a855c918bdce811724da93c4 wp-block-paragraph\" style=\"font-style:normal;font-weight:600\">We treat atopic dermatitis, rosacea, and seborrheic dermatitis.<br\/><\/p>\n\n\n\n<p class=\"has-custom-color-5-color has-text-color has-link-color has-superbfont-small-font-size wp-elements-b0ed9896cd87c4dc29ef35753e45458c wp-block-paragraph\">Thanks to the valuable reviews you have shared in the community, many of you visit us even from far away.<br\/>We will repay you with sincere, attentive care.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-custom-color-6-color has-alpha-channel-opacity has-custom-color-6-background-color has-background is-style-wide\"\/>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e1e686a6 wp-block-columns-is-layout-flex\" style=\"padding-top:0;padding-bottom:0\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-19afc361 wp-block-group-is-layout-flex\">\n<p class=\"has-custom-color-3-color has-text-color has-link-color has-superbfont-small-font-size wp-elements-5046f5cbf2504632740a9221c469d447 wp-block-paragraph\"><strong>DK Han<\/strong><\/p>\n\n\n\n<p class=\"has-custom-color-5-color has-text-color has-link-color has-superbfont-xsmall-font-size wp-elements-f628b1a898e0079d43059baed3da5249 wp-block-paragraph\">Chief Director, MIRAGEN Clinic<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p class=\"has-custom-color-5-color has-text-color has-link-color has-superbfont-xsmall-font-size wp-elements-0a159b55280bf6519f7c0f2e7a7ab305 wp-block-paragraph\">Graduate of University of Michigan, Ross School of Business<br\/>Graduate of Chungnam National University School of Medicine<br\/>(Former) Representative Director of Ewha Phoenix Rehabilitation Hospital<br\/>(Current) Representative Director of MIRAGEN Clinic<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Among patients visiting for chronic dermatitis, there are rare cases where individuals purchase Rutinib ointment through overseas direct buying services. They often ask, &#8220;I tried it because it&#8217;s said to have the same ingredients as the new drug Opzelura; is it okay to use?&#8221; This is a difficult question to answer briefly. It is true [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":12599,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_miragen_jsonld":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-12598","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-1"],"_links":{"self":[{"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/posts\/12598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/comments?post=12598"}],"version-history":[{"count":2,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/posts\/12598\/revisions"}],"predecessor-version":[{"id":12601,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/posts\/12598\/revisions\/12601"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/media\/12599"}],"wp:attachment":[{"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/media?parent=12598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/categories?post=12598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/tags?post=12598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}